Balchem Corporation

Balchem Corporation(BCPC)股票分析

$173.230

+2.477 (+1.43%)收盤時

Loading chart…
最高
173.430
開盤
170.680
成交量加權均價
172.40
成交量
493.94K
市值
4.92B
最低
170.540
成交金額
85.15M
企業價值/稅息折舊攤銷前利潤(TTM)
18.66

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

AI 分析 of Balchem Corporation (BCPC)

買進

Balchem Corp is a good buy right now due to its strong financial performance, with a current price of $170.73 and a forward P/E ratio of 29.33, indicating reasonable valuation relative to growth expectations. The company reported a 11.2% year-over-year revenue growth in Q2 2026, reaching $284 million, which exceeded expectations. However, the main risk is the high RSI of 72.67, indicating that the stock may be overbought in the short term.

估值指標

Balchem Corporation(BCPC)目前預期本益比為 29.33,5 年平均預期本益比為 32.62。

預期本益比

合理
5 年均值 P/E
32.62
目前P/E
29.33
高估
35.96
低估
29.28

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
20.53
目前EV/EBITDA
18.66
高估
22.61
低估
18.46

預期股價營收比

合理
5 年均值 P/S
4.77
目前P/S
4.55
高估
5.35
低估
4.20

Alphio AI 對 BCPC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BCPC

$162.17

情境價格

基

基準

基準 · 50%BCPC

$159.96

情境價格

悲

悲觀

悲觀 · 25%BCPC

$150.29

情境價格

持有 BCPC 的大戶

S

Salem Investment Counselors, Inc.

+ 持有BCPC

+4.04%

3個月報酬率

W

Wasatch Advisors LP

+ 持有BCPC

-0.53%

3個月報酬率

N

Nationwide Fund Advisors

+ 持有BCPC

-2.53%

3個月報酬率

事件時間軸

2026-07-31 (ET)

07:31:00

Balchem Reports Q2 Revenue of $284M

2026-04-30 (ET)

07:50:00

Balchem Q1 Revenue $270.71M Beats Consensus

2026-03-09 (ET)

08:20:00

Balchem Launches Metalosate T.E.A.M. Plant Tissue Analysis Platform

2026-02-20 (ET)

07:20:00

Balchem Reports Q4 Revenue of $263.6M

2025-12-22 (ET)

08:10:00

Eastman and Balchem Welcome EU's Anti-Dumping Duties on Choline Chloride Imports from China

資訊

BCPC 常見問題 —— 由 Alphio AI 解答

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. It operates in the Basic Materials sector (CHEMICALS & ALLIED PRODUCTS industry).

Balchem Corp is a good buy right now due to its strong financial performance, with a current price of $170.73 and a forward P/E ratio of 29.33, indicating reasonable valuation relative to growth expectations. The company reported a 11.2% year-over-year revenue growth in Q2 2026, reaching $284 million, which exceeded expectations. However, the main risk is the high RSI of 72.67, indicating that the stock may be overbought in the short term.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易